(Q43767544)

26 November 2017

1 reference

title

Problems and current solutions for the treatment of infections caused by gram-positive microorganisms (English)

1 reference

26 November 2017

main subject

gram-positive bacteria

0 references

author name string

Grau S

1

1 reference

26 November 2017

Alvarez-Lerma F

2

1 reference

26 November 2017

Marín M

3

1 reference

26 November 2017

Luis Gimeno J

4

1 reference

26 November 2017

publication date

1 October 2001

1 reference

Infectious Diseases and Clinical Microbiology

26 November 2017

published in

1 reference

26 November 2017

volume

19

1 reference

26 November 2017

issue

8

1 reference

26 November 2017

page(s)

393-398

1 reference

Vancomycin-resistant Staphylococcus aureus: infection control considerations

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

Antibiotic resistance in Spain: what can be done? Task Force of the General Direction for Health Planning of the Spanish Ministry of Health

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

The epidemiology of antimicrobial resistance in hospital acquired infections: problems and possible solutions

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid) during a worldwide clinical program

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

Quinupristin-dalfopristin

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infect

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

Novelties in the field of anti-infectives in 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

In-vitro antimicrobial activity of HMR 3004 (RU 64004) against erythromycin A-sensitive and -resistant Corynebacterium spp. isolated from clinical specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

Daptomycin: a novel agent for Gram-positive infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032)

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

Daptomycin disrupts membrane potential in growing Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

Influence of subinhibitory concentrations of loracarbef (LY 163892) and daptomycin (LY 146032) on bacterial phagocytosis, killing and serum sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972671-7

7 January 2021

10.1016/S0213-005X(01)72671-7

Identifiers

DOI

1 reference

26 November 2017

1 reference